# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenera...
Needham analyst David Saxon reiterates CryoPort (NASDAQ:CYRX) with a Buy and maintains $18 price target.
CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.35) by...
B. Riley Securities analyst Yuan Zhi downgrades CryoPort (NASDAQ:CYRX) from Buy to Neutral and lowers the price target from ...